We are live on ! Find out more
SABS icon

SAB Biotherapeutics

26 hedge funds and large institutions have $65.9M invested in SAB Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

45.33% more ownership

Funds ownership: 0% → 45.33% (+45%)

Holders
26
Holders Change
+26
Holders Change %
–
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SABS Hedge Fund Activity: Q1 2021 in Review

26 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2021, worth a combined $65.9M.

Buyers outnumbered sellers: 26 funds opened new SABS positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Basso Capital Management, opening a new position worth an estimated $6.87M.

  • 26 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $65.9M of SAB Biotherapeutics stock for Q1 2021.
  • 26 funds opened new SAB Biotherapeutics positions in Q1 2021 and 0 closed out, a net change of +26 holders.
  • The largest SAB Biotherapeutics buyer in Q1 2021 was Basso Capital Management, an estimated $6.87M added.

Based on aggregated 13F filings for Q1 2021.